Introduction and Objective: Anatomic and volumetric changes occur in head-and-neck cancer during fractionated radiotherapy (RT), and the actual dose received by patient is considerably different from the original plan. The purpose of this study is to evaluate volumetric and dosimetric changes occurring during radiation therapy.
INTRODUCTION
Intensity-modulated radiotherapy (IMRT) has become the standard treatment in locally advanced head-and-neck cancer (LAHNC) because of its high conformality, with potential sparing of critical structures. [1, 2] During head-and-neck radiotherapy (RT), changes in anatomy occur during treatment course. Changes include shrinkage of tumor and normal tissues and positional shift of certain structures, which is due to response to radiation and combined chemotherapy. [3] The planning target volume (PTV) includes margin for uncertainties in shape and motion of organs, beam geometry, and patient setup. However, this PTV does not account for weight loss, tumor shrinkage, and tissue edema (anatomical alterations). [4] Hence, little alteration in patient's anatomy and position results in huge dosimetric changes (lower dose to target volume and high dose to organ at risks [OARs] ) because of sharp dose gradients between target volume (TV) and OARs in IMRT. [5] This might lead to increased complications and marginal recurrences. To minimize these limitations, the possible strategy is adaptive RT (ART), i.e., repeat imaging and replanning to adapt to actual patient anatomy.
In this study, we evaluated the dosimetric and volumetric changes occurring during IMRT This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. treatment for LAHNC and also to estimate the benefits of adaptive radiation therapy.
PATIENTS AND METHODS
Ten patients of Stage III-IVb LAHNC were analyzed prospectively between November 2015 and December 2016. Inclusion criteria were as follows: (i) Histologically proven squamous cell carcinoma of oropharynx, larynx, and hypopharynx; (ii) Age in the range of 18-70 years; and (iii) Eastern Cooperative Oncology Group performance score 0-2.
Primary objective
The primary objective was to evaluate the volumetric and dosimetric alterations occurring during RT treatment in LAHNC.
Treatment planning
All patients underwent RT treatment planning scan. A plain and contrast computed tomography (CT) scan for RT planning was done after immobilization with 5-clamp head-and-neck mask in treatment position as per departmental protocol. 3-mm slice thickness axial images from frontal sinus to carina were acquired and all data were sent through DICOM-Digital Imaging and Communications in Medicine to a workstation treatment planning system (TPS; Eclipse integrated treatment planning system, version 10) through local area network.
The primary tumor and abnormal lymph node in neck were delineated on CT images. The Clinical Target Volume (CTV) were named as CTV1-high risk volumes enclosing the gross tumor volumes; CTV2-low risk volumes of elective nodal regions. PTV margin of 5 mm was used for setup errors. Dose prescribed to PTV1 was 70Gy/35 fractions and PTV2 was 50Gy/25 fractions.
IMRT plans were generated with sliding window technique using nine coplanar equidistant fields of 6 MV energy. Optimizations and dose calculations were done with Eclipse version 10 (Varian Medical Systems). Treatment was delivered once daily, 5 days/week, over 7 weeks, using Varian (CLINAC iX) linear accelerator.
Adaptive radiotherapy-computed tomography re-simulation and intensity-modulated radiotherapy replanning All patients were followed up once a week during treatment. The change in weight loss was monitored. After 4 weeks, re-CT simulation was done for each patient with new immobilization mask. Re-contouring of TV and OARs was done and noted. Original plan (OPLAN), i.e,. planning done on the first CT scan was implemented for the whole course of RT treatment. The initial plan is implemented on the second planning CT scan, and the dose distribution is recalculated. IMRT replan (RPLAN) was generated on the second CT scan to observe dosimetric changes. Beam configuration of OPLAN was applied onto the second CT scan and then hybrid plan (HPLAN) was generated. (HPLAN situation when no replanning would have occurred.) Anatomical changes were compared between 2 scans after 4 weeks (20 fractions) of RT. To ensure dosimetric consistency between two plans, OPLAN30 (based on the first CT scan for the remaining 30 Gy) was compared to HPLAN30 (Hybrid plan for 30 Gy). To evaluate the effect of replanning on dosimetric outcome, HPLAN30 was compared with IMRT replan (RPLAN30). All these comparisons are for the remaining fractions delivered after the second CT scan. All patients underwent IMRT along with concurrent weekly injection of cisplatin.
Statistical analysis
Linear variables were summarized as mean and standard deviation as descriptive statistics. Between-group comparison of linear variables was done using unpaired t-test, whereas Wilcoxon rank sum test was used for paired observations of linear variables within the groups. P <0.05 was considered statistically significant. Med Calc version 12.2.1.0 software (MedCalc Software, Acacialaan 22, B-8400 Ostend, Belgium) was used for all statistical calculations. Table 1 .
RESULTS

Patient characteristics are summarized in
Volumetric analysis
Comparison of volumes of PTV and OARs (parotids) between day 1 CT and mid CT scan was performed. Mean shrinkage of PTV and parotids (ipsilateral and contralateral) in mid treatment scan was statistically significant (P < 0.05).
Dosimetric analysis
Impact of anatomical changes in PTV and OARs on dosimetric outcome was evaluated. Dosimetric characteristics are summarized in Table 2 . D98%/D95% (tumor coverage) on comparing OPLAN30 versus HPLAN30 (P = 0.098) and HPLAN30 versus RPLAN30 (P = 0.084) was statistically insignificant. There was a significant difference in D2% (OPLAN30 versus HPLAN30, P = 0.016 and HPLAN30 versus RLAN30, P = 0.015). On comparing planned and delivered doses, an increase on V 107% was seen (P = 0.049). The comparison of dose distribution of TV of OPLAN, HPLAN, and RPLAN is shown in Figure 1 .
Spinal cord A significant increase in D max and D1% of spinal cord was seen in HPLAN30 when compared to that of OPLAN30 (P = 0.019). Replanning reduced D max and D1% of spinal cord (P = 0.004).
Parotid D e l i v e re d ( H P L A N ) m e a n d o s e o f c o n t r a l a t e r a l parotid (22 ± 5.46 Gy) was higher than the planned (OPLAN) mean dose (20.30 ± 2.64 Gy), for which we further reduced the contralateral parotid mean dose by replanning (16.74 ± 7 Gy). A similar pattern was observed in ipsilateral parotid but was not significant.
DISCUSSION
IMRT increases therapeutic ratio by increasing dose to target and reducing doses to OARs. Due to its high conformality, steep dose gradients exist around TV. A small change in anatomical/positional variations results in underdosage to TV and higher doses to OARs. In this study, we quantified changes occurring during RT treatment and the effect of replanning on dose distribution.
Weight loss is a common presentation during RT treatment in LAHNC. Ho et al. reported a 7.6% median weight loss during the entire course of treatment. [6] Bhandari et al., reported that 10% weight loss was observed after the 3 rd week of RT. [1] In comparison with the above studies, mean weight loss in our study was 7.99% in the first 4 weeks and three patients required nasogastric tube for nutritional support.
Marked anatomical changes have been observed during treatment either due to shrinkage of primary tumor and nodal volumes or weight loss. Vasquez Osorio et al. observed 25 ± 15% reduction in primary tumor volume in patients who underwent resimulation after 46 Gy. [7] In our study on comparison of PTV between the 1 st and 2 nd CT scan, there is significant reduction in mean PTV (146.3 cc, 13.1%, P = 0.034). These volumetric changes, i.e., reduction in volume is also seen in parotids. Due to weight loss or TV reduction, parotids shift medially into a high-dose region. Studies have observed significant volume loss of parotids during RT. [5, 6, [8] [9] [10] [11] [12] [13] Selected studies showing TV reduction and parotid volume contraction are depicted in Table 3 . In the present study, there is a significant reduction in ipsilateral parotid (mean % decrease: −27.3%, P = 0.008) and contralateral parotid (−24.63%, P = 0.008) after 4 weeks.
We have also evaluated the impact of anatomical modification on dosimetry. Dosimetric modifications between planned (OPLAN30), delivered (HPLAN30), and adaptive (RPLAN30) doses were performed. Delivered doses (D98%/D95%) did not significantly differ from planned doses to PTV but with a significant increase in D2% in HPLAN30 (P = 0.016), which was reduced by replanning (P = 0.015). In studies by Castadot et al. and Wu et al., there was no significant change between planned and delivered doses with respect to PTV coverage. [3, 13] Spinal cord and parotids received more actual delivered dose than planned dose (P < 0.05) which could be reduced by replanning. Studies showing increase in dose to OARs (spinal cord and parotids) if not replanned and time for replanning are depicted in Table 4 . Adaptive replanned doses (D2%) are significantly smaller than delivered doses. RPLAN30 for D max and D1% of spinal cord was significantly smaller than that of HPLAN30 (P = 0.004 and P = 0.008, respectively). In our study, mid treatment re-scanning and re-planning reduced doses to OARs. The increased doses to ipsilateral and contralateral parotid glands and spinal cord in hybrid plan (that we do not want) are 1.59 Gy, 1.7 Gy, and 3.3 Gy (D max ), respectively. We reduced these extra doses to OARs by mid treatment replanning. Timing for replanning is a crucial challenge. There are no clear consensus guidelines for replanning. The timing for replanning is shown in Table 4 . We have also analyzed skin doses and its clinical effect. The skin doses (D mean ) in OPLAN30, HPLAN30, and RPLAN30 are 10.88 Gy, 12.25 Gy, and 7.88 Gy, respectively. Nearly 80% of patients have Grade I and 20% have Grade II skin reactions.
CONCLUSION
This study evaluated the serial change in volume and dosimetric changes in TV and OARs in LAHNC patients receiving chemo-IMRT. The significant volume and dosimetric changes occur 4 weeks after commencing RT. The sharp dose gradients in IMRT force us to minimize uncertainties (anatomical and positional variations) to reduce geographic miss. ART by rescanning, recontouring, and replanning is required if necessary. Our study demonstrated the mid treatment re-CT simulation and adaptive planning reduced doses to OARs.
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CTV1=Volume enclosing macroscopic disease and areas at high risk of harboring microscopic disease, PTV=Planning target volume, HPLAN=Hybrid plan, OPLAN=Original plan 
Study Inference
Increased parotid dose if not replanned Castelli et al. [15] Average increase of parotid gland dose is 3.7Gy (D mean ) Weekly replanning reduced Dmean by 5.1Gy Wu et al. [3] Increase of D mean by ~10% Replanning + reduced margins decreased 30% of parotid D mean Lee et al. [16] 10% increase in mean parotid dose Han et al. [12] The average median dose increased from 83.0 cGy to 142.6 cGy, with an average increase rate of 1.7 cGy/treatment day Jensen et al. [11] The median parotid dose increase in ipsilateral parotid was 3.87% and contralateral parotid was 11.5% Cheng et al. [8] I/L parotid (Gy) C/L parotid (Gy) 
Study
Study Inference
Timing for replanning Wu et al. [3] Replan at week 4 Wang et al. [9] Replan before 25 th fraction Cheng et al. [8] Replan at 30 Gy Woodford et al. [17] Adaptive replanning if GTV decreased by >30% at any point during the first 20 fractions Bhandari et al. [1] Repeat scan if BMI >25 kg/m 2 OPLAN=Original plan, HPLAN=Hybrid plan, RPLAN=Replan, I/L=Ipsilateral, C/L=Contralateral. GTV=Gross tumor volume, BMI=Body mass index
